Dr. Visco discusses the surgical and patient benefits of continuous intracameral administration of OMIDRIA.
This retrospective study shows that patients receiving OMIDRIA and topical NSAID without postoperative topical steroids had lower rates of CME, breakthrough iritis, and pain after cataract surgery when compared with conventional perioperative topical steroids.
This retrospective study demonstrated a reduction in the quantity of opioids prescribed for patients receiving OMIDRIA during cataract surgery. The study also hypothesized that the use of OMIDRIA intraoperatively may decrease patient exposure to opioids after cataract surgery as well as the volume of pills potentially diverted into the community.
This prospective study demonstrated that patients treated with OMIDRIA had a statistically significant lower use of fentanyl intraoperatively while also experiencing significantly less pain than those treated with epinephrine.
Learn why Dr. Visco uses OMIDRIA at her ASC to deliver a better experience to surgical patients.
Hear Dr. Walter share the benefits of OMIDRIA in both patient chair time and improved outcomes.
Listen to Dr. Silverstein discuss how maintaining pupil size during cataract surgery plays a key role in achieving a positive surgical experience and positive patient outcomes.
Learn about real world evidence studies that show lower rates of post-operative CME and why it makes sense to have OMIDRIA on board
See why Dr. Walter describes OMIDRIA as a great red-zone defense.
Dr. Silverstein discusses how OMIDRIA significantly reduced all 3 facets of IFIS in this real world study among male patients with a history of tamsulosin usage.
Drs Wiley and Hura share how OMIDRIA contributes to the art of refractive cataract surgery
Expanding the focus beyond the immediate intraoperative benefits of OMIDRIA
Listen to Drs Wiley and Hura discuss why they started using OMIDRIA and how implementing it has led to an improved surgical experience for patients, surgeons, and staff.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat…
OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.
OMIDRIA must be added to irrigating solution prior to intraocular use.
OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.
Systemic exposure to phenylephrine may cause elevations in blood pressure.
Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.
The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.
Please see the Full Prescribing Information for OMIDRIA.
You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
This site is intended for US Physician educational purposes only, using scientific exchange around the OMIDRIA experience.
Rayner, the Rayner logo, OMIDRIA, the OMIDRIA logo, and OMIDRIAssure are proprietary marks of Rayner. ©2022 Rayner Group, all rights reserved. US-OM-2200071 12/22
